Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a prostate cancer scan also spot liver tumors?

NCT ID NCT05095519

Diagnosis Sponsor: Peter MacCallum Cancer Centre, Australia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial is testing whether a special PET/CT scan, typically used for prostate cancer, can better detect hepatocellular carcinoma (the most common type of liver cancer) compared to standard CT or MRI scans. The study will enroll about 30 adults with liver lesions suspicious for cancer. Participants will receive an injection of a radioactive tracer called 18F-DCFPyL, which binds to PSMA, a protein that may be present on liver cancer cells. The goal is to see if this scan can accurately identify cancerous lesions, potentially improving diagnosis and reducing the need for invasive biopsies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-DCFPyL, a radioactive tracer used for PSMA PET/CT imaging
What this could lead to
If successful, this imaging approach could offer a more accurate, non-invasive way to detect liver cancer, potentially reducing the need for biopsies.
What could go wrong
This is a small pilot study, so results may not be definitive. The tracer may not reliably distinguish liver cancer from other conditions, and there is a small radiation exposure risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

30 people

The number who actually took part.

Started

Sep 2021

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female aged 18 years or older at screening * Has provided written informed consent for participation in the study * Must have risk factors for HCC e.g. cirrhosis, chronic hepatitis B infection with or without cirrhosis * Patients with liver lesions ≥1 cm suspicious for HCC but with indeterminate features on CT and MRI meeting LI-RADS 3 or 4 criteria planned for biopsy, OR patients with liver lesions diagnostic of HCC based on CT or MRI meeting LI-RADS 5 criteria planned for surgical resection * Patients must be willing and able to comply with the protocol and procedures for the duration of the study * Patients must be available for follow-up Exclusion Criteria: * Abdominal surgery or radiotherapy to the abdomen within \<4 weeks of registration. Patients must have recovered from any effects of any major surgery * Uncontrolled intercurrent illness that is likely to impede participation and or compliance * Any history of prostate cancer or elevated PSA level for male patients * Other malignancies unless curatively treated with no evidence of disease within previous 3-years other than adequately treated non-melanoma skin cancer or melanoma in situ * Participation in another clinical study with an investigational product or another systemic cancer therapy administered in the last 4 weeks * Has known psychiatric or substance abuse disorders that would interfere with cooperation with requirements of the study * Women who are pregnant or lactating * Cirrhosis due to congenital hepatic fibrosis, vascular disorders (e.g. Budd-Chiari syndrome) or cardiac cirrhosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Austin Health

    Heidelberg, Victoria, 3084, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • St Vincent's Hospital

    Fitzroy, Victoria, 3065, Australia

  • The Royal Melbourne Hospital

    Melbourne, Victoria, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.